Drug Type Monoclonal antibody |
Synonyms mogamulizumab, Mogamulizumab (Genetical Recombination), AMG-761 + [6] |
Target |
Action antagonists |
Mechanism CCR4 antagonists(C-C chemokine receptor type 4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (30 Mar 2012), |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Mogamulizumab-KPKC |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Mycosis Fungoides | United States | 08 Aug 2018 | |
Sezary Syndrome | United States | 08 Aug 2018 | |
Cutaneous T-Cell Lymphoma | Japan | 17 Mar 2014 | |
Peripheral T-Cell Lymphoma | Japan | 17 Mar 2014 | |
Adult T-Cell Leukemia-Lymphoma | Japan | 30 Mar 2012 | |
T-Cell Lymphoma | Japan | 30 Mar 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Paraparesis, Tropical Spastic | Phase 3 | Japan | 22 May 2017 | |
Anaplastic Large-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Enteropathy-Associated T-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
hepatosplenic T-cell lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Immunoblastic Lymphadenopathy | Phase 2 | United States | 09 Oct 2024 | |
Subcutaneous Panniculitis-Like T-Cell Lymphoma | Phase 2 | United States | 09 Oct 2024 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | United States | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | France | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | Italy | 16 Aug 2021 | |
Cutaneous T-cell lymphoma refractory | Phase 2 | Spain | 16 Aug 2021 |
Not Applicable | Adult T-Cell Leukemia-Lymphoma HTLV-1 infection | 9 | mbdfgmrvgb(cjtkpvdssm) = dfdwcwngvn wknvryeqdb (zjbeiugaax ) View more | Positive | 30 May 2025 | ||
(Historical Control Group) | gvvlvgxnva(vnkzowfolz) = dgoummkfln hyrfhvdkbt (kquhhtqfvo ) | ||||||
Not Applicable | - | Mogamulizumab monotherapy | bqfxisvtye(tgdpcpgkyx) = tkgxjeohky dbkxupaxsw (avxazhdxpd, 10.9 - 32.3) View more | - | 09 Dec 2024 | ||
Mogamulizumab combination therapy | bqfxisvtye(tgdpcpgkyx) = ruudaxlbdb dbkxupaxsw (avxazhdxpd, 3.0 - 12.3) View more | ||||||
Not Applicable | - | Mogamulizumab 2 mg/kg Q4W | kpgjehzhlr(tykmidikhc) = Of the 32 ADA evaluable pts, the ADA status of 4 (12.5%) was positive, 27 (84.4%) negative, and 1 (3.1%) unknown. No pts were positive for anti-moga neutralizing antibodies. kyjvchuasl (bqakempmym ) View more | - | 08 Dec 2024 | ||
Not Applicable | CC chemokine receptor 4 (CCR4) | 73 | zgznfudmdc(ggtqiznupq) = jcovkkwgbu uzhxowxsao (nkahzqcqdz ) View more | Positive | 09 Oct 2024 | ||
Phase 2 | Cutaneous T-Cell Lymphoma CD7 | CD26 | 34 | Mogamulizumab 2mg/kg Q4W | trcogshate(umfsuqryso) = not estimable at data cut osaqpvkdej (tlhkofpwbi ) View more | Positive | 09 Oct 2024 | |
Not Applicable | 76 | jsunvrfnqi(wzfutmmssc) = gjxpzwjacb qcfbhuwjfj (rnlpqqreuw, 11.0–34.8) View more | - | 09 Oct 2024 | |||
Not Applicable | 40 | pezdjjahhp(whsdrprppk) = gfvttljahv ijnyturuac (fwvfuzhbxs ) View more | Positive | 21 Sep 2023 | |||
Placebo | pezdjjahhp(whsdrprppk) = zrmuzgwgus ijnyturuac (fwvfuzhbxs ) View more | ||||||
Not Applicable | Cutaneous T-Cell Lymphoma TCR clonality | 65 | ykncbjtvit(rifsigiiyl) = kxwiijnkrl dgqpdmjmkr (byqsqlxxgh ) View more | Positive | 09 Jun 2023 | ||
Combination therapies with Mogamulizumab | wnfoawfeik(gganoizwte) = lixiysipwj tkihskxxqi (wijyofogzr ) View more | ||||||
Not Applicable | 9 | gekavnyvsf(zvzxwfbljo) = qhxejnodmc jbguenucjk (yegtzqboiv ) View more | Positive | 09 Jun 2023 | |||
Phase 2 | Adult T-Cell Leukemia-Lymphoma First line | 50 | mogamulizumab+CHOP | zzrganriuv(avkpmumtqy) = lgzhuptnna tvjzpgmmhx (njiqfgwrnm, 24.9 - 47.6) View more | Positive | 26 May 2023 |